Oscar Health Past Earnings Performance
Past criteria checks 0/6
Oscar Health has been growing earnings at an average annual rate of 39%, while the Insurance industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 40.1% per year.
Key information
38.96%
Earnings growth rate
69.87%
EPS growth rate
| Insurance Industry Growth | 8.02% |
| Revenue growth rate | 40.13% |
| Return on equity | -13.83% |
| Net Margin | -1.50% |
| Last Earnings Update | 30 Jun 2025 |
Recent past performance updates
Recent updates
Oscar Health Ahead Of Q2: Brace For Strategic Reset
Aug 04Not Many Are Piling Into Oscar Health, Inc. (NYSE:OSCR) Stock Yet As It Plummets 36%
Jul 22
Oscar Health, Inc. (NYSE:OSCR) Might Not Be As Mispriced As It Looks After Plunging 27%
Apr 09Oscar Health: The Most Undervalued Small Cap But With One Big Risk
Mar 09Oscar Health: Looking Like A Cheap High-Growth Company, But Not Without A Catch
Feb 13Oscar Health: Trump Uncertainty Creates Buying Opportunity
Jan 20Investors Give Oscar Health, Inc. (NYSE:OSCR) Shares A 25% Hiding
Dec 20Not Many Are Piling Into Oscar Health, Inc. (NYSE:OSCR) Stock Yet As It Plummets 27%
Oct 29Not Many Are Piling Into Oscar Health, Inc. (NYSE:OSCR) Just Yet
Sep 13Oscar Health: At Nearly 4x Book Value Investors Should Wait For A Pullback
Sep 03
Innovative Insurance Strategies Poised To Revolutionize Market Presence And Profitability
Expanding into new insurance markets and innovating products for diverse customers are expected to significantly drive Oscar Health's revenue growth.Oscar Health: Achieves Profitability In Q1 2024, But Uncertainties Remain
Jul 02Results: Oscar Health, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 11Investors Still Aren't Entirely Convinced By Oscar Health, Inc.'s (NYSE:OSCR) Revenues Despite 30% Price Jump
May 03Oscar Health: Strong Industry Catalyst With Margin Expansion Potential
Apr 13This Analyst Just Made An Upgrade To Their Oscar Health, Inc. (NYSE:OSCR) Earnings Forecasts
Feb 12Oscar Health, Inc. (NYSE:OSCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 10Oscar Health: Flexible Business Model Is Paying Off
Jan 30Further Upside For Oscar Health, Inc. (NYSE:OSCR) Shares Could Introduce Price Risks After 37% Bounce
Jan 19Oscar Health, Inc. (NYSE:OSCR) Soars 49% But It's A Story Of Risk Vs Reward
Nov 21Oscar Health: Q3 Earnings Suggest Growth Can Continue Into 2024
Nov 15Oscar Health: Decreasing Memberships Is Worrying
Sep 22Oscar Health Shares Quadrupled, But They Are Still Cheap
Jul 03Oscar Health: High Growth And Improving Profitability Make It A Buy
Jun 15Revenue & Expenses Breakdown
How Oscar Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 10,726 | -161 | 1,943 | 0 |
| 31 Mar 25 | 10,082 | 123 | 1,844 | 0 |
| 31 Dec 24 | 9,178 | 25 | 1,756 | 0 |
| 30 Sep 24 | 8,215 | 29 | 971 | 0 |
| 30 Jun 24 | 7,233 | 18 | 1,519 | 0 |
| 31 Mar 24 | 6,535 | -54 | 1,375 | 0 |
| 31 Dec 23 | 5,863 | -271 | 1,379 | 0 |
| 30 Sep 23 | 5,437 | -347 | 1,176 | 0 |
| 30 Jun 23 | 4,982 | -474 | 1,013 | 0 |
| 31 Mar 23 | 4,482 | -571 | 884 | 0 |
| 31 Dec 22 | 3,964 | -606 | 1,257 | 0 |
| 30 Sep 22 | 3,519 | -579 | 607 | 0 |
| 30 Jun 22 | 2,983 | -598 | 521 | 0 |
| 31 Mar 22 | 2,491 | -559 | 466 | 0 |
| 31 Dec 21 | 1,894 | -573 | 446 | 0 |
| 30 Sep 21 | 1,439 | -571 | 365 | 0 |
| 30 Jun 21 | 1,096 | -439 | 351 | 0 |
| 31 Mar 21 | 682 | -406 | 304 | 0 |
| 31 Dec 20 | 391 | -414 | 267 | 0 |
| 31 Dec 19 | 476 | -261 | 159 | 0 |
Quality Earnings: OSCR is currently unprofitable.
Growing Profit Margin: OSCR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OSCR is unprofitable, but has reduced losses over the past 5 years at a rate of 39% per year.
Accelerating Growth: Unable to compare OSCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSCR is unprofitable, making it difficult to compare its past year earnings growth to the Insurance industry (8.7%).
Return on Equity
High ROE: OSCR has a negative Return on Equity (-13.83%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/10 12:03 |
| End of Day Share Price | 2025/08/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oscar Health, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hua Ha | Baird |
| Andrew Mok | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |